Accumulation of alpha-synuclein (α-syn) is central to the pathogenesis of Parkinson's disease (PD). Previous studies suggest that α-syn pathology may originate from the olfactory bulb (OB) or gut in response to an unknown pathogen and later progress to the different brain regions. Aging is viewed as the utmost threat to PD development. Therefore, studies depicting the role of age in α-syn accumulation and its progression in PD are important. In the present study, we gave intranasal rotenone microemulsion for 6 weeks in 12-month-old female BALB/c mice and found olfactory dysfunction after 4 and 6 weeks of rotenone administration. Interestingly, motor impairment was observed only after 6 weeks. The animals were sacrificed after 6 weeks to perform western blotting and immunohistochemical studies to detect α-syn pathology, neuroinflammation and neurodegeneration. We found α-syn accumulation in OB, striatum, substantia nigra (SN) and cortex. Importantly, we found significant glial cell activation and neurodegeneration in all the analysed regions which were absent in our previous published studies with 3 months old mice even after they were exposed to rotenone for 9 weeks indicating age is a crucial factor for α-syn induced neuroinflammation and neurodegeneration. We also observed increased iron accumulation in SN of rotenone-exposed aged mice. Moreover, inflammaging was observed in OB and striatum of 12-month-old BALB/c mice as compared to 3-month-old BALB/c mice. In conclusion, there is a difference in sensitivity between adult and aged mice in the development and progression of α-syn pathology and subsequent neurodegeneration, for which inflammaging might be the crucial probable mechanism.

Department of Pharmacology and Toxicology National Institute of Pharmaceutical Education and Research Palaj Ahmedabad Gandhinagar 382355 Gujarat India

International Clinical Research Center St Anne's University Hospital Brno Brno Czech Republic ICRC FNUSA Brno Czech Republic

Zobrazit více v PubMed

De Rijk M, Breteler M, Graveland G, Ott A, Grobbee D, Van der Meche F, Hofman A (1995) Prevalence of parkinson’s disease in the elderly: the rotterdam study. Neurology 45:2143–2146 PubMed DOI

Gómez-Benito M, Granado N, García-Sanz P, Michel A, Dumoulin M, Moratalla R (2020) Modeling Parkinson’s disease with the alpha-synuclein protein. Front Pharmacol 11:356 PubMed DOI PMC

Lee H-J, Suk J-E, Lee K-W, Park S-H, Blumbergs PC, Gai W-P, Lee S-J (2011) Transmission of synucleinopathies in the enteric nervous system of A53T alpha-synuclein transgenic mice. Exp Neurobiol 20:181 PubMed DOI PMC

Malek N, Swallow D, Grosset K, Anichtchik O, Spillantini M, Grosset D (2014) Alpha-synuclein in peripheral tissues and body fluids as a biomarker for P arkinson’s disease–a systematic review. Acta Neurol Scand 130:59–72 PubMed DOI

Uemura N, Yagi H, Uemura MT, Hatanaka Y, Yamakado H, Takahashi R (2018) Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve. Mol Neurodegener 13:1–11 DOI

Sui X, Zhou C, Li J, Chen L, Yang X, Li F (2019) Hyposmia as a predictive marker of Parkinson’s disease: a systematic review and meta-analysis. BioMed Res Int 2019:1–9

Yu Q-J, Yu S-Y, Zuo L-J, Lian T-H, Hu Y, Wang R-D, Piao Y-S, Guo P, Liu L, Jin Z (2018) Parkinson disease with constipation: clinical features and relevant factors. Sci Rep 8:1–9

Roos DS, Twisk JW, Raijmakers PG, Doty RL, Berendse HW (2019) Hyposmia as a marker of (non-) motor disease severity in Parkinson’s disease. J Neural Transm 126:1471–1478 PubMed DOI

Braak H, Del Tredici K, Rüb U, De Vos RA, Steur ENJ, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211 PubMed DOI

Braak H, Del Tredici K (2017) Neuropathological staging of brain pathology in sporadic Parkinson’s disease: separating the wheat from the chaff. J Parkinsons Dis 7:S71–S85 PubMed DOI PMC

Chen H, Wang K, Scheperjans F, Killinger B (2022) Environmental triggers of Parkinson’s disease–implications of the braak and dual-hit hypotheses. Neurobiol Dis 163:105601 PubMed DOI

Hawkes CH, Del Tredici K, Braak H (2007) Parkinson’s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 33:599–614 PubMed DOI PMC

Rey NL, Petit GH, Bousset L, Melki R, Brundin P (2013) Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol 126:555–573 PubMed DOI PMC

Rey NL, Steiner JA, Maroof N, Luk KC, Madaj Z, Trojanowski JQ, Lee VM-Y, Brundin P (2016) Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson’s disease. J Exp Med 213:1759–1778 PubMed DOI PMC

Rey NL, Wesson DW, Brundin P (2018) The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases. Neurobiol Dis 109:226–248 PubMed DOI

Reeve A, Simcox E, Turnbull D (2014) Ageing and Parkinson’s disease: why is advancing age the biggest risk factor? Ageing Res Rev 14:19–30 PubMed DOI PMC

Buchman AS, Shulman JM, Nag S, Leurgans SE, Arnold SE, Morris MC, Schneider JA, Bennett DA (2012) Nigral pathology and parkinsonian signs in elders without Parkinson disease. Ann Neurol 71:258–266 PubMed DOI PMC

Mattson MP, Arumugam TV (2018) Hallmarks of brain aging: adaptive and pathological modification by metabolic states. Cell Metab 27:1176–1199 PubMed DOI PMC

Vila M (2019) Neuromelanin, aging, and neuronal vulnerability in Parkinson’s disease. Mov Disord 34:1440–1451 PubMed DOI PMC

Bilgic B, Pfefferbaum A, Rohlfing T, Sullivan EV, Adalsteinsson E (2012) MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. Neuroimage 59:2625–2635 PubMed DOI

Dexter D, Wells F, Lee A, Agid F, Agid Y, Jenner P, Marsden C (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease. J Neurochem 52:1830–1836 PubMed DOI

Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L (2014) The role of iron in brain ageing and neurodegenerative disorders. The Lancet Neurology 13:1045–1060 PubMed DOI PMC

Kosta P, Argyropoulou MI, Markoula S, Konitsiotis S (2006) MRI evaluation of the basal ganglia size and iron content in patients with Parkinson’s disease. J Neurol 253:26–32 PubMed DOI

Rossi ME, Ruottinen H, Saunamäki T, Elovaara I, Dastidar P (2014) Imaging brain iron and diffusion patterns: a follow-up study of Parkinson’s disease in the initial stages. Acad Radiol 21:64–71 PubMed DOI

Zecca L, Zucca FA, Wilms H, Sulzer D (2003) Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci 26:578–580 PubMed DOI

Zecca L, Gallorini M, Schünemann V, Trautwein AX, Gerlach M, Riederer P, Vezzoni P, Tampellini D (2001) Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem 76:1766–1773 PubMed DOI

He L-q, Lu J-h, Yue Z-y (2013) Autophagy in ageing and ageing-associated diseases. Acta Pharmacol Sin 34:605–611 PubMed DOI PMC

Lynch-Day MA, Mao K, Wang K, Zhao M, Klionsky DJ (2012) The role of autophagy in Parkinson’s disease. Cold Spring Harb Perspect Med 2:a009357 PubMed DOI PMC

Parekh P, Sharma N, Gadepalli A, Shahane A, Sharma M, Khairnar A (2019) A cleaning crew: the pursuit of autophagy in Parkinson’s disease. ACS Chem Neurosci 10:3914–3926 PubMed DOI

Calabrese V, Santoro A, Monti D, Crupi R, Di Paola R, Latteri S, Cuzzocrea S, Zappia M, Giordano J, Calabrese EJ (2018) Aging and Parkinson’s disease: inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis. Free Radical Biol Med 115:80–91 DOI

Amor S, Peferoen LA, Vogel DY, Breur M, van der Valk P, Baker D, van Noort JM (2014) Inflammation in neurodegenerative diseases–an update. Immunology 142:151–166 PubMed DOI PMC

Ransohoff RM (2016) How neuroinflammation contributes to neurodegeneration. Science 353:777–783 PubMed DOI

Calabrese V, Cornelius C, Dinkova-Kostova AT, Calabrese EJ, Mattson MP (2010) Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid Redox Signal 13:1763–1811 PubMed DOI PMC

Zhang Y, Ahn Y-H, Benjamin IJ, Honda T, Hicks RJ, Calabrese V, Cole PA, Dinkova-Kostova AT (2011) HSF1-dependent upregulation of Hsp70 by sulfhydryl-reactive inducers of the KEAP1/NRF2/ARE pathway. Chem Biol 18:1355–1361 PubMed DOI PMC

Calabrese EJ, Iavicoli I, Calabrese V (2012) Hormesis: why it is important to biogerontologists. Biogerontology 13:215–235 PubMed DOI

Salvioli S, Capri M, Valensin S, Tieri P, Monti D, Ottaviani E, Franceschi C (2006) Inflamm-aging, cytokines and aging: state of the art, new hypotheses on the role of mitochondria and new perspectives from systems biology. Curr Pharm Des 12:3161–3171 PubMed DOI

Codolo G, Plotegher N, Pozzobon T, Brucale M, Tessari I, Bubacco L, de Bernard M (2013) Triggering of inflammasome by aggregated α–synuclein, an inflammatory response in synucleinopathies. PLoS ONE 8:e55375 PubMed DOI PMC

Lu M, Sun X-L, Qiao C, Liu Y, Ding J-H, Hu G (2014) Uncoupling protein 2 deficiency aggravates astrocytic endoplasmic reticulum stress and nod-like receptor protein 3 inflammasome activation. Neurobiol Aging 35:421–430 PubMed DOI

Yan Y, Jiang W, Liu L, Wang X, Ding C, Tian Z, Zhou R (2015) Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell 160:62–73 PubMed DOI

Mao Z, Liu C, Ji S, Yang Q, Ye H, Han H, Xue Z (2017) The NLRP3 inflammasome is involved in the pathogenesis of Parkinson’s disease in rats. Neurochem Res 42:1104–1115 PubMed DOI

Sharma M, Kaur J, Rakshe S, Sharma N, Khunt D, Khairnar A (2022) Intranasal exposure to low-dose rotenone induced alpha-synuclein accumulation and parkinson’s like symptoms without loss of dopaminergic neurons. Neurotox Res 40:215–229 PubMed DOI

Sasajima H, Miyazono S, Noguchi T, Kashiwayanagi M (2017) Intranasal administration of rotenone to mice induces dopaminergic neurite degeneration of dopaminergic neurons in the substantia nigra. Biol Pharm Bull 40:108–112 PubMed DOI

Rabl R, Breitschaedel C, Flunkert S, Duller S, Amschl D, Neddens J, Niederkofler V, Rockenstein E, Masliah E, Roemer H (2017) Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice. BMC Neurosci 18:1–12 DOI

Mamiya T, Ukai M (2001) [Gly14]-Humanin improved the learning and memory impairment induced by scopolamine in vivo. Br J Pharmacol 134:1597–1599 PubMed DOI PMC

Parkhe A, Parekh P, Nalla LV, Sharma N, Sharma M, Gadepalli A, Kate A, Khairnar A (2020) Protective effect of alpha mangostin on rotenone induced toxicity in rat model of Parkinson’s disease. Neurosci Lett 716:134652 PubMed DOI

Khairnar A, Plumitallo A, Frau L, Schintu N, Morelli M (2010) Caffeine enhances astroglia and microglia reactivity induced by 3, 4-methylenedioxymethamphetamine (‘ecstasy’) in mouse brain. Neurotox Res 17:435–439 PubMed DOI

Ip CW, Cheong D, Volkmann J (2017) Stereological estimation of dopaminergic neuron number in the mouse substantia nigra using the optical fractionator and standard microscopy equipment. JoVE J Vis Exp 127:e56103

Farrand AQ, Verner RS, McGuire RM, Helke KL, Hinson VK, Boger HA (2020) Differential effects of vagus nerve stimulation paradigms guide clinical development for Parkinson’s disease. Brain Stimul 13:1323–1332 PubMed DOI

Guo J-J, Yue F, Song D-Y, Bousset L, Liang X, Tang J, Yuan L, Li W, Melki R, Tang Y (2021) Intranasal administration of α-synuclein preformed fibrils triggers microglial iron deposition in the substantia nigra of Macaca fascicularis. Cell Death Dis 12:1–14 DOI

Wang Q, Liu Y, Zhou J (2015) Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl Neurodegener 4:1–9 DOI

Park T, Chen H, Kevala K, Lee J-W, Kim H-Y (2016) N-Docosahexaenoylethanolamine ameliorates LPS-induced neuroinflammation via cAMP/PKA-dependent signaling. J Neuroinflammation 13:1–15 DOI

Tabrez S, Jabir NR, Shakil S, Greig NH, Alam Q, Abuzenadah AM, Damanhouri GA, Kamal MA (2012) A synopsis on the role of tyrosine hydroxylase in Parkinson’s disease. CNS Neurol Disord-Drug Targets Former Curr Drug Targets-CNS Neurol Disord 11:395–409

Dunkley PR, Bobrovskaya L, Graham ME, Von Nagy-Felsobuki EI, Dickson PW (2004) Tyrosine hydroxylase phosphorylation: regulation and consequences. J Neurochem 91:1025–1043 PubMed DOI

Driver-Dunckley E, Adler CH, Hentz JG, Dugger BN, Shill HA, Caviness JN, Sabbagh MN, Beach TG, Consortium APD (2014) Olfactory dysfunction in incidental Lewy body disease and Parkinson’s disease. Parkinsonism Relat Disord 20:1260–1262 PubMed DOI PMC

Rey NL, George S, Steiner JA, Madaj Z, Luk KC, Trojanowski JQ, Lee VM-Y, Brundin P (2018) Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term. Acta Neuropathol 135:65–83 PubMed DOI

Lashuel HA, Overk CR, Oueslati A, Masliah E (2013) The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14:38–48 PubMed DOI PMC

Sala G, Arosio A, Stefanoni G, Melchionda L, Riva C, Marinig D, Brighina L, Ferrarese C (2013) Rotenone upregulates alpha-synuclein and myocyte enhancer factor 2D independently from lysosomal degradation inhibition. BioMed Res Int 2013:1–10 DOI

Niu H, Wang Q, Zhao W, Liu J, Wang D, Muhammad B, Liu X, Quan N, Zhang H, Zhang F (2020) IL-1β/IL-1R1 signaling induced by intranasal lipopolysaccharide infusion regulates alpha-Synuclein pathology in the olfactory bulb, substantia nigra and striatum. Brain Pathol 30:1102–1118 PubMed DOI PMC

Van Den Berge N, Ferreira N, Mikkelsen TW, Alstrup AKO, Tamgüney G, Karlsson P, Terkelsen AJ, Nyengaard JR, Jensen PH, Borghammer P (2021) Ageing promotes pathological alpha-synuclein propagation and autonomic dysfunction in wild-type rats. Brain 144:1853–1868 PubMed DOI

Tai H-C, Schuman EM (2008) Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nat Rev Neurosci 9:826–838 PubMed DOI

Liu Y, Zhang Y, Zhu K, Chi S, Wang C, Xie A (2020) Emerging role of Sirtuin 2 in Parkinson’s disease. Front Aging Neurosci 11:372 PubMed DOI PMC

Hindle JV (2010) Ageing, neurodegeneration and Parkinson’s disease. Age Ageing 39:156–161 PubMed DOI

Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V (2022) Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol 22:657–673 PubMed DOI PMC

McGeer PL, McGeer EG (2008) Glial reactions in Parkinson’s disease. Mov Disord: Off J Mov Disord Soc 23:474–483 DOI

Godbout J, Chen J, Abraham J, Richwine A, Berg B, Kelley K, Johnson R (2005) Exaggerated neuroinflammation and sickness behavior in aged mice after activation of the peripheral innate immune system. FASEB J 19:1329–1331 PubMed DOI

Sparkman NL, Johnson RW (2008) Neuroinflammation associated with aging sensitizes the brain to the effects of infection or stress. NeuroImmunoModulation 15:323–330 PubMed DOI

Norden DM, Godbout J (2013) Microglia of the aged brain: primed to be activated and resistant to regulation. Neuropathol Appl Neurobiol 39:19–34 PubMed DOI PMC

Gritsenko A, Green JP, Brough D, Lopez-Castejon G (2020) Mechanisms of NLRP3 priming in inflammaging and age related diseases. Cytokine Growth Factor Rev 55:15–25 PubMed DOI PMC

Drake J, Sultana R, Aksenova M, Calabrese V, Butterfield DA (2003) Elevation of mitochondrial glutathione by γ-glutamylcysteine ethyl ester protects mitochondria against peroxynitrite-induced oxidative stress. J Neurosci Res 74:917–927 PubMed DOI

Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, Giuffrida Stella AM (2007) Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci 8:766–775 PubMed DOI

Griffiths P, Dobson B, Jones G, Clarke D (1999) Iron in the basal ganglia in Parkinson’s disease: an in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 122:667–673 PubMed DOI

Dexter D, Wells F, Agid F, Agid Y, Lees A, Jenner P, Marsden C (1987) Increased nigral iron content in postmortem parkinsonian brain. The Lancet 330:1219–1220 DOI

Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds G, Hebenstreit G, Youdim M (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74:199–205 PubMed DOI

Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MB (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52:515–520 PubMed DOI

Dexter D, Carayon A, Javoy-Agid F, Agid Y, Wells F, Daniel S, Lees A, Jenner P, Marsden C (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114:1953–1975 PubMed DOI

Chen B, Wen X, Jiang H, Wang J, Song N, Xie J (2019) Interactions between iron and α-synuclein pathology in Parkinson’s disease. Free Radical Biol Med 141:253–260 DOI

Ortega R, Carmona A, Roudeau S, Perrin L, Dučić T, Carboni E, Bohic S, Cloetens P, Lingor P (2016) α-Synuclein over-expression induces increased iron accumulation and redistribution in iron-exposed neurons. Mol Neurobiol 53:1925–1934 PubMed DOI

Chronic DSS-Induced Colitis Exacerbates Parkinson's Disease Phenotype and Its Pathological Features Following Intragastric Rotenone Exposure

Hyperglycemia-Driven Insulin Signaling Defects Promote Parkinson's Disease-like Pathology in Mice